ADReCS

Pharmaceutical Information

Drug Name	Cefaclor
Drug ID	BADD_D00378
Description	Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.
Indications and Usage	For the treatment of certain infections caused by bacteria such as pneumonia and ear, lung, skin, throat, and urinary tract infections.
Marketing Status	approved
ATC Code	J01DC04
DrugBank ID	DB00833
KEGG ID	D00256; D02352
MeSH ID	D002433
PubChem ID	51039
TTD Drug ID	D0PW7C
NDC Product Code	0093-1087; 23594-250; 23594-375; 23594-125; 61442-171; 61442-172; 81948-6250
UNII	69K7K19H4L
Synonyms	Cefaclor \| Cefaclor Anhydrous \| Keclor \| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))- \| S-6472 \| S 6472 \| S6472 \| Ceclor \| Cefaclor Monohydrate \| Lilly 99638

Chemical Information

Molecular Formula	C15H14ClN3O4S
CAS Registry Number	53994-73-3
SMILES	C1C(=C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Somnolence	19.02.05.003; 17.02.04.006	-	-
Stevens-Johnson syndrome	10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005	-	-
Stomatitis	07.05.06.005	-	-
Superinfection	11.01.08.009	-	-	Not Available
Swelling face	08.01.03.100; 23.04.01.018; 10.01.05.018	0.000049%		Not Available
Syncope	02.11.04.015; 24.06.02.012; 17.02.04.008	-	-
Tension	19.06.02.005	-	-	Not Available
Thrombocytopenia	01.08.01.002	-	-	Not Available
Thrombocytosis	01.08.02.001	-	-	Not Available
Tongue oedema	10.01.05.008; 07.14.02.007; 23.04.01.009	-	-	Not Available
Tooth discolouration	07.09.02.001	-	-
Toxic epidermal necrolysis	11.07.01.006; 10.01.01.006; 23.03.01.008; 12.03.01.015	-	-
Tremor	17.01.06.002	-	-
Urethral disorder	20.07.01.002	-	-	Not Available
Urinary tract disorder	20.08.01.001	-	-	Not Available
Urine glucose false positive	13.02.02.006	-	-	Not Available
Urticaria	23.04.02.001; 10.01.06.001	0.000073%
Vaginal discharge	21.08.02.002	-	-
Vaginal infection	21.14.02.002; 11.01.10.002	-	-
Vasodilatation	24.03.02.003; 23.06.05.006	-	-	Not Available
Vertigo	04.04.01.003; 17.02.12.002	-	-
Vomiting	07.01.07.003	0.000097%
Vulvovaginal candidiasis	21.14.02.003; 11.03.03.005	-	-	Not Available
Wheezing	22.03.01.009	-	-
Tubulointerstitial nephritis	20.05.02.002	-	-	Not Available
Lymphatic disorder	01.09.01.003	-	-	Not Available
Musculoskeletal discomfort	15.03.04.001	-	-	Not Available
Type IV hypersensitivity reaction	10.01.03.022	0.000049%		Not Available
Affect lability	19.04.01.001	-	-	Not Available
Foetal death	18.01.02.003; 08.04.01.011	0.000146%

The 6th Page First Pre 6 7 Next Last Total 7 Pages